Phytohealth Corporation · TWSE:4108
Phytohealth — 2023 Institutional Investor Conference
27 slides from Phytohealth's conference presentation, Nov 28, 2023
Slide 1: Phytohealth Corporation
Phytohealth Corporation Taiwan Stock Exchange (symbol:4108) 2023 Institutional Investor Conference Established: 1998 Stock Exchange Listed: 2008 Capitalization: USD 70M Chairperson: Yili Lee CEO Angel Lee
Slide 2: Statement
Statement 1.Apart from historical data, the matters listed in this presentation that are forward-looking statements may be subject to significant risks and uncertainties, which could result in differences between these forward-looking statements and actual outcomes. 2.The future projections presente
Slide 3: Company Profile
Company Profile TY (7127005 PhytoHealth Corporation
Slide 4: PhytoHealth aims to apply the latest pharmaceutical drug development techniques
PhytoHealth aims to apply the latest pharmaceutical drug development techniques to innovate natural treatments used for thousands of years in Chinese botanical medicine practices to satisfy the unmet clinical needs.
Slide 5: Key milestones of Phytohealth Corporation
Key milestones of Phytohealth Corporation Company 1998 established 2002 Company public listing Listed on OTC as the first new drug R&D company 2008 • 1st botanical drug NDA • 1st oral nalbuphine received approval (PG2®) • API manufacturing factory NDA approval (Oraphine®) attained PIC/S GMP approval
Slide 6: PhytoHealth Project Pipeline
PhytoHealth Project Pipeline
Slide 7: Global market for botanical and plant-derived drugs
$38B The global market for USD in 2023 botanical and plant-derived drugs has show continual growth over the last decade and is showing promise to continue moving forward at $50B steady pace. USD by 2029 4.78% *Botanical and Plant-derived Drugs: Global CAGR Markets, BCC Research
Slide 8: Key factors holding back botanical drug markets
Key factors holding back botanical drug markets Botanical Drug Guidance 1 3 2 Sufficient efficacy Key factors 3 Market traction
Slide 9: Our Track Record of Success
Our Track Record of Success Regulatory Evidence of Market Growth Approval Efficacy 1st New TFDA License 19 Research Articles PG2 is reimbursed by Taiwan For Prescription Botanical on PG2 found in top 25% National Health issuance. Drug issued by TFDA Leading Medical & the1st botanical drug (April, 20
Slide 10: Sharing our Value Chain
Sharing our Value Chain R&D - Unmet Need in oncology, anti- COVID-19..etc Manufacturing PhytoHealth’s API Plant awarded with PIC/S GMP Certificate RWE - Data generation & Publication - CME program Sales & Marketing - Market Access strategy: self –pay & reimbursement - Focus on Hospital Channel - Pat
Slide 11: 2022-2023 Key progress
y 2022-2023 Key p EY (7 (28 709 PhytoHealth Corporation
Slide 12: Publication at the 2023 ASCO annual meeting
1. Publication at the 2023 ASCO (American Society of Clinical Oncology) annual meeting
Slide 13: 2023 June ASCO - PG2 Abstract
2023 June ASCO -PG2® Abstract Breast cancer clinical trials Period：02.21.18~12.31.21 (On 8/31’21 All patients have completed the trial) Execution agencies: E-Da Cancer Hospital, Linkou, Chang Gung Memorial Hospital, Taipei and Kaohsiung Chang Gung Memorial Hospital Accepted: 67 persons Evaluable: 61
Slide 14: 2023 PG2 Publication at Clinical Conference
2023 PG2® Publication at Clinical Conference Academic publication Journal or medical society Item Name of the papers date name The 8th Biennial Meeting of Combination of Astragalus Polysaccharides (PG2) to reduce 12/1/2023- Asian Society of Persistent Cancer-related Fatigue in Gynecologic Cancer 1 1
Slide 15: Strengthen clinical decision making in Cancer-Related Fatigue
2. Strengthen clinical decision making in Cancer-Related Fatigue
Slide 16: 92% of patients have cancer-related fatigue
92% of patients have cancer-related fatigue According to the "Guidelines of Management of Cancer related Fatigue1” Astragals polysaccharide injection (PG2® ) is recommended to treat moderate to sever cancer related fatigue (Level 1A, Grade A Recommendation ) 1. Management of Cancer Related Fatigue i
Slide 17: Strengthen decision-making for CRF
Strengthen decision-making for CRF Medical Association Continuing Education Patient RWE Group CRF R53.0* (CRF, Cancer Related Fatigue)
Slide 18: Launch Oraphine Globally
3. Launch Oraphine®Globally
Slide 19: Oraphine 60mg Soft Capsule
Oraphine® 60mg@soft Capsule : a new treatment choice to treat moderate to severe pain Oraphine® is the first choice of oral analgesia for moderate to severe pain because it provides rapid onset, powerful efficacy and better safety profile. • Now in use in major hospitals in Taiwan 19
Slide 20: BIO Conference and Exhibition
4. BIO Conference and Exhibition
Slide 21: 2023 US BIO Boston Taiwan Pavilion: Phytohealth
2023 US BIO Boston Taiwan Pavilion: Phytohealth
Slide 22: Nutritional supplements
5. Nutritional supplements ool tO sce Ra AD PhytoHealth Corporation
Slide 23: Phytohealth entered nutritional supplement market
Phytohealth entered nutritional supplement market with the spirit of new drug research and development Astragalus Anti- Health care expert cancer professional expert Technology Requirements Brand World Leading technology of Focus first on highly professional Phytohealth—an botanical drug refined ast
Slide 24: Financial information
Financial information TY (7 12 7005 PhytoHealth Corporation
Slide 25: Balance Sheet
Sound financial structure 1. Sufficient cash 「Balance Sheet」 2. Low debts ratio 單位:仟元 科 目 112.9.30 % 111.12.31 % CURRENT ASSETS 1,521,568 65 1,568,464 66 NON-CURRENT 824,139 35 796,164 34 TOTAL ASSETS 2,345,707 100 2,364,628 100 CURRENT LIABILITIES 52,644 2 62,118 3 NON-CURRENT 25,117 1 25,057 1 TOT
Slide 26: Income statement
1.Net sales grew 14% 「Income statement」 2.Net loss reduced 65% 單位:仟元 112 1-9 111 1-9月 +-% Account (A) % (B) % (A-B)/B Net Sales 115,885 100 101,651 100 14 Gross Margin 48,274 42 42,790 42 13 Operating Exp. (127,702) (110) (144,372) (191) (12) Operating Loss (79,428) (68) (101,522) (149) (22) Non-ope
Slide 27: 27
27